Bruker (BRKR) Downgraded to “Hold” at BidaskClub

Bruker (NASDAQ:BRKR) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday, BidAskClub reports.

Several other analysts also recently commented on the stock. Needham & Company LLC started coverage on shares of Bruker in a research report on Wednesday, January 2nd. They issued a “strong-buy” rating and a $39.00 target price for the company. BTIG Research reissued a “buy” rating and issued a $44.00 target price (up from $42.00) on shares of Bruker in a research report on Tuesday, February 12th. ValuEngine raised shares of Bruker from a “hold” rating to a “buy” rating in a research report on Tuesday, January 15th. Deutsche Bank raised shares of Bruker from a “hold” rating to a “buy” rating and boosted their target price for the stock from $40.00 to $50.00 in a research report on Friday, April 12th. Finally, Zacks Investment Research downgraded shares of Bruker from a “buy” rating to a “hold” rating in a research report on Tuesday. Two analysts have rated the stock with a sell rating, three have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Bruker presently has an average rating of “Hold” and an average price target of $38.14.

Bruker stock opened at $38.17 on Friday. The company has a market capitalization of $6.09 billion, a price-to-earnings ratio of 27.26, a P/E/G ratio of 2.18 and a beta of 1.47. The company has a current ratio of 2.18, a quick ratio of 1.33 and a debt-to-equity ratio of 0.36. Bruker has a twelve month low of $26.10 and a twelve month high of $40.25.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Monday, February 11th. The medical research company reported $0.54 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.54. The firm had revenue of $553.60 million for the quarter, compared to analyst estimates of $544.53 million. Bruker had a net margin of 9.48% and a return on equity of 26.36%. Equities research analysts forecast that Bruker will post 1.57 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Chicago Equity Partners LLC boosted its holdings in shares of Bruker by 4.4% during the 4th quarter. Chicago Equity Partners LLC now owns 9,415 shares of the medical research company’s stock worth $280,000 after buying an additional 400 shares during the period. State Board of Administration of Florida Retirement System boosted its holdings in shares of Bruker by 0.4% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 144,802 shares of the medical research company’s stock worth $4,311,000 after buying an additional 510 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Bruker by 8.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,136 shares of the medical research company’s stock worth $212,000 after buying an additional 550 shares during the period. Hanseatic Management Services Inc. boosted its holdings in shares of Bruker by 52.0% during the 4th quarter. Hanseatic Management Services Inc. now owns 1,692 shares of the medical research company’s stock worth $50,000 after buying an additional 579 shares during the period. Finally, Strs Ohio boosted its holdings in shares of Bruker by 6.2% during the 4th quarter. Strs Ohio now owns 10,148 shares of the medical research company’s stock worth $302,000 after buying an additional 591 shares during the period. 68.89% of the stock is owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Further Reading: Stock Symbol

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.